9th Cir.;
14-35933
The court of appeals affirmed in part, reversed in part, and vacated in part a judgment and remanded. The court held that securities fraud class action plaintiffs adequately alleged that a company’s statements regarding the Food and Drug Administration (FDA) approval of one of its lead products were both false and material.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
